Get started

Predictions

SHIP Retraced...Now What?SHIP retraced back to the 50 fib finally, bounced and now attempting to get back to the 236 area but recent volume has ben lighter than in previous weeks. As it approaches this area yet again, I think volume will ultimately dictate the next move. Sure, you've got supply chain bottlenecks and higher prices for shipping specifically to Capesize vessels. However, industry fundamentals have their tipping points. Seanergy isn’t vocal via its newswire; however, its Twitter feed has become a soapbox of sorts. The company has made it known that there’s a significant value in Cape vessel rates right now. A recent tweet explained that cape vessel rates were $75k/day and that “SHIP has unique benefit through index-linked contracts for most of the fleet.” Other than that, SHIP stock price movement has reflected a similar tone in a direction that other reopening stocks have seen. SHIP Stock Forecast Maxim is the most recent analyst to weigh in on SHIP stock. The firm upgraded its rating to Buy and announced a $2.50 price target . Based on open prices on October 8, this target is 78% higher.
NASDAQ:SHIP
by PennyStocks101
1
RSLS Short Term Retracement Still Showing LevelsOnly did the fib retracement back til July because before that the levels are just absurdly higher. So sticking to some level of relevance, we can start to see what areas have materialized as potentially "important" in my opinion. For RSLS , the 786 fib has been a level of high traffic and pivot for the stock. It was previous support back in July and into August, then turned into resistance ever since. Similar to Kosmos, ReShape hasn’t released much recent news. However, a new VP of Operations and R&D in August along with more substantial revenues for the quarter have been two things traders have focused on. Furthermore, insider buying from CFO Thomas Stankovich this summer came as a vote of confidence for some. Stankovich picked up nearly $50,000 worth of RSLS stock toward the end of August. However, the company has presented at several industry events and was given a notice of allowance by the US Patent & Trademark Office titled “Intragastric Device” late last month. RSLS Stock Forecast According to the World Health Organization, worldwide obesity has nearly tripled since 1975. With an ever-growing population, there remains a constant need for helping those hit by this disease. This week Maxim Group initiated coverage on ReShape with a Buy rating and a price target 167% higher than retail levels on October 8th. Maxim joins other analysts like Alliance Global, who also has a hefty price target on RSLS stock . It sits at $10.25 or roughly 290% higher than where RSLS opened on Friday.
NASDAQ:RSLS
by PennyStocks101
2
KOS...They Said So? Bullish Resistance Or Bearish Deflection 2.0This is a familiar area for KOS that has taken some time to get to. But now that its back at the 382 fib level, the proof will be in the pudding. This was an area of previous support a few months back and now KOS is desperately trying to make it so once again. Over the last few weeks it's been deflected but continues hovering in the area so all may not be lost (for now). Other than earnings released in August, there haven’t been many new updates from the company. For the most part, KOS stock has moved with the overall oil and gas market direction. When it comes to Kosmos Energy’s last earnings update, it experienced increased revenues and a more narrow adjusted loss. KOS Stock Forecast Similar to American Resources, analysts may be bullish on Kosmos thanks to the reopening trade. Higher energy demand has put somewhat of a strain on the portion of the raw material of the supply chain. With that has come higher inflation and, thus, higher prices. In light of this, it might make more sense that analysts at firms like Sanford Berstein have given a stamp of approval with an Outperform rating . The firm also has a $7.80 price target, roughly 140% higher than opening levels on October 8.
NYSE:KOS
by PennyStocks101
AREC Stuck In Traffic...againAREC caught a nice pop in daily trading volume over the last few days/week. But this 786 fib line remains a sticky area of traffic that is still a clear area of resistance on the chart. This week has been a busy one for American Resources. Updates include progress on its battery recycling initiative with Purdue University achieving 99.5% purity of lithium, cobalt, and nickel. In addition, the company acquired additional mineral reserves for its Deep Mine at the Perry County Resources complex. These reserves include an estimated 10.1 million tons of mineral resources. AREC Stock Forecast Clearly, American Resources has become a part of the budding reopening trade. Thanks to global economies piping money into infrastructure redevelopment and new projects, raw materials are at the core of the supply chain. In light of this, would it surprise you that analysts are bullish? Right now, HC Wainwright’s Heiko Ihle has a Buy on AREC stock with a price target 80% higher than opening trading levels on Friday, which is $4.
NASDAQ:AREC
by PennyStocks101
Solana (SOL) price speculation and where it’s going. Where is Solana heading in the near term — to long term? This post isn’t necessarily my personal prediction of SOL. I’m simply pointing out what I’m seeing in the daily chart, as well I take into consideration recent events that could be a catalyst for a price change in Solana. I’d like to hear all of your thoughts and opinions as to what you think will happen. Also, I would enjoy your feedback on my chart and basically everything I say. There’s really only two ways to grow Either someone tells you that you’re wrong — then change up whatever you’re messing up — hopefully getting it right in the future. Someone points out that you’re actually doing it the right way, perhaps making some suggestions, but otherwise tells you to stay on the same track you’ve been taking. Obviously there’s a lot more to it than that, but I’m sure most would agree that sums it up in a general sort of way. So, what are your thoughts on Solana? Will it keep going up? RSI looks good — holding above the 50 lvl which indicates buying strength, yet not in overbought territory — although it seems to be dipping down. MACD looks to be making a Bullish Crossover as you read this — according to the Daily Chart. That is typically a very bullish indicator — if coupled with other confirmations. I’d like to see the 1 hour chart with the ICH Cloud for further confirmation of the MACD crossover — I learned a cool tip — the one hour chart with ICH Cloud Indicator acts like the daily MACD, but on a faster timeframe and more reactive to real time price changes. I apologize for the spelling — the ICH Cloud is the Ichiomo Cloud? I have no clue how to spell it and don’t feel like looking it up, but I’m sure most of your know what I mean. If not, sImply Google ICH Cloud Indicator and it’ll correct it for you. Finally, we’re holding above old resistance levels and can safely say that they have now become strong support. Further strength in the uptrend can be confirmed due to the price holding or (walking) on the middle Bollinger Band. If price falls below the middle band, watch for a quick dip buy opportunity, assuming that the price rebounds and goes back above the middle band to close out for the trading day. Of course, considering that Crypto trades 24/7 — determining the “close of trading day” is going to be different for everyone and arguably doesn’t exist. I live in the Pacific Time Zone so I like to watch for these things to “Close” around 7-8 pm — as I noticed that this is when the markets seem to calm down a bit. But, this is subjective to where you live or if you even believe in a “Close” at all. Overall, even though I see strength in SOL’s chart and the news has been great regarding Solana recently — the Wormhole Testnet was a success and it’s proven that SOL can handle a much larger volume of transactions than say, ETH. . . For some reason I see SOL doing another run up to perhaps hit its previous all time high, only to come falling back down. Essentially repeating the same price pattern we just saw it go through a few weeks ago. Long term — I think Solana is going to be a main player in Web3 and will find itself a stable, permanent role in the ecosystem of dApps, DeFi, and many other applications that will be popping up with insane regularity as Web3 comes to the masses. You can’t have Web3 without SOL — so long term I see SOL being a $1,500 - $2,000 coin on the market. Perhaps higher, but not less. Short to mid term — people will get FOMO in the following days, buying up all the SOL they can, then when the “pros” and day traders feel like they have pumped it high enough, got the hook set in nice and tight in the FOMO-Filled-Coinbase-retail-traders. . . They’ll dump, taking profits and we’ll be back to where we’re at now, give or take $20. Remember — WHAT ARE YOUR THOUGHTS? Do you agree? Do you completely disagree? Is my charting and analysis completely wrong and I have no idea what I’m talking about — or is my does my prediction sound pretty accurate, with my charts aligning with my claims? I hope to hear from as many of your as possible. Thanks. Btw… the reason I am asking for feedback is because of my last prediction. I have it linked. I saw a perfect ascending triangle pattern forming in FORTHS Chart a while back, but something happened and it never panned out!?! I am still baffled by that one to this day! Check out the link after your done with this one. Perhaps you can tell me where I went wrong.
COINBASE:SOLUSDLong
by thinkordrown
1
Don't get too excited yet - Bitcoin Weekly AnalasysDon't get too excited over a 10% price jump within a 25% price correction. We still have to break this EXTREME resistence at 49-50k. Not only is there major resistence on many trend indicators, but Bitcoin had also broken below two parabolic curved lines following its bullrun which currently is at around 50.1k and stands as a potential major rejection point on larger timeframes. Trade safe, use stops and think in terms of probabilities.
by mastertrade23
CEI 382 & 50 Fib Levels Are ImportantCEI has been one of the penny stocks we've written about on the site for weeks now. Since it was at just 35 cents, the stock has been on fire. Of course, taking out the social media hype factor, there are potential technical levels to consider right now. First, the 50 fib line has been an initial level of traffic over the last few months. Whenever CEI has gotten to this point, it has either failed to break or briefly break above and hold as interim support. However, as you can see the last time it jumped above this level, it was fleeting. This time around, there's a lot more daily volume at above-average levels to take into account. What's more, you can see that 382 has consistently remained an upper level of support/resistance, more times acting as resistance (as it did Friday), than support. But again, given the above-average volume, that is something that is very different this time around. Then you've got strength in energy stocks, in general. That paired with these technical levels could be something to watch heading into the new week and end of the third quarter. You've also got Finviz showing short interest above 24% as of Friday.
C
by PennyStocks101
SENS Continues Holding LevelsPulled SENS back up again after a few weeks and see that it's still holding the same fib and trendline levels as it was when we first drew out the fib retracement. It's also now holding the 50DMA consistently as it steadily rises. For some context, this company develops and commercializes continuous glucose monitoring systems for diabetes patients. Senseonics offers the Eversense and Eversense XL products in its lineup. These are implantable CGM systems for measuring glucose levels with an under-skin sensor, and a removable and rechargeable smart transmitter. Sensonics also offers an app for real-time diabetes metrics monitoring. Other Highlights: - HC Wainwright $6 target and buy rating last month - Collab with University Hospitals Accountable Care Organization - Raised $50 million in gross proceeds through completion of At-the-Market equity offering program last quarter. Proceeds earmarked "primarily for debt service" -Year-To-Date up over 320% so far
AMEX:SENS
by PennyStocks101
US30 THE END ?Wall Street dipped on Wednesday on concerns that the spread of the Delta coronavirus variant could slow economic growth and on uncertainty over the timeline for the Federal Reserve to pull back its accommodative policies. Shares of tech heavyweights were among losers with Microsoft Corp (NASDAQ:MSFT), Facebook Inc (NASDAQ:FB) and Google-owner Alphabet (NASDAQ:GOOGL) Inc were down between 0.1% and 0.6%. Nine out of eleven sub-sectors fell with economy-sensitive sectors like industrials, materials and real estate leading declines. Gains in energy shares helped limit some losses with Exxon Mobil (NYSE:XOM), Chevron (NYSE:CVX), Occidental Petroleum (NYSE:OXY) and Halliburton (NYSE:HAL) up between 0.6% and 0.3%, as oil prices jumped on lower output. U.S. stocks have come under pressure in recent days as investors have turned increasingly cautious following Friday's weak August payrolls data and uncertainty over the Fed's tapering. "The big question is the uncertainty around the level of economic growth slowdown, tapering and the potential of escalating inflation," said Sam Stovall, chief investment strategist at CFRA. "Investors are thinking they don't want to be highly exposed towards potential growth sectors, instead the interest remains towards the safety of tech stocks." St. Louis Federal Reserve Bank President James Bullard told the Financial Times that the U.S. Federal Reserve should move forward with a plan to trim its massive pandemic stimulus program despite a slowdown in job growth. Stovall said CFRA economists are lowering the growth forecasts for the third quarter, but were still optimistic for the wider economy to grow for the rest of the year. The S&P 500 and the Nasdaq have gained around 20% so far this year on support from easy central bank policies, but a jump in coronavirus infections and weak economic data have raised worries on the pace of economic recovery. At 10:17 a.m. ET, the Dow Jones Industrial Average was down 11.74 points, or 0.03%, at 35,088.26, the S&P 500 was down 2.96 points, or 0.07%, at 4,517.07, and the Nasdaq Composite was down 43.66 points, or 0.28%, at 15,330.67. Perrigo Company (NYSE:PRGO) Plc jumped 6.1% after the drugmaker said it plans to buy HRA Pharma from investment firms Astorg and Goldman Sachs (NYSE:GS) Asset Management in a deal valued at 1.8 billion euros ($2.13 billion). Cryptocurrency exchange Coinbase (NASDAQ:COIN) Global Inc fell 3.5% after the U.S. securities regulator threatened to sue the firm if it goes ahead with plans to launch a crypto lending scheme. Declining issues outnumbered advancers for a 1.29-to-1 ratio on the NYSE and for a 2.13-to-1 ratio on the Nasdaq. The S&P index recorded 13 new 52-week highs and one new low, while the Nasdaq recorded 31 new highs and 16 new lows.
UShort
by globalsymmetrygroup
Will It VRPX Right By This Resistance Or Fail Again?VRPX is another one of the former penny stock darlings of the year. Big breakout mid August put it on everyone's radars now it's about sustaining this higher price level and subsequent valuation. At today's price of around $20.25, the market cap is 3.5x the size it was just a few weeks ago. Thanks to FDA related headlines, VRPX stock skyrocketed. "The FDA has indicated that Virpax may pursue an NDA drug approval with the Office of Non-Prescription Drugs. The Company has engaged Syneos Health to assist with the optimal clinical trial design based on an efficient timeline." Now that it seems to have found a home north of $15, levels are coming to light. Right now it looks like the 50 fib line is that pivot. Following the big breakout it was somewhat of a "no man's land support" and now it has acted as resistance, rejecting VRPX each time it's been tested. However, the last few days have seen an uptick in daily volumes so that could be something to keep a closer eye on right now. "Regarding the latter, VRPX stock is the latest penny stock darling to experience an explosive move. Monday afternoon, shares were trading below $4.50 & as of mid-morning on Tuesday, the former penny stock broke above $10 a share. Now, if you’re wondering what the VRPX stock forecast is moving forward, your guess is as good as mine. In parabolic instances like this, fundamentals can begin playing a role to justify a stock’s price being so highly valued... VPRX isn’t the only trending penny stock today. Retail traders are posting images of Robinhood charts that include other big movers..." Read More Link: 4 Trending Penny Stocks On Robinhood You Should Watch Right Now
NASDAQ:VRPX
by PennyStocks101
KALA Levels + Short InfoShort squeeze stocks have become a favorite recently. KALA has started getting wrapped into the conversation. Looking at details from sites like FinViz, short float is around 20% meanwhile the float itself shows to be around 42 million shares. Plotting some levels, you'll notice that KALA is still in the lower channel on the fib retracement slowly heading toward the 786 area. However, before that happens, keep watch on an interim level around $3.40. It was previously a support level in July but seems to have become a resistance level as KALA was strongly rejected right at $3.40 on Friday. Aside from the technical/speculative trend, there are also a few things to watch with the company after a rough first half: " Kala specializes in eye treatments. Its EYSUVIS is quickly playing a leading role for the company. According to the company, this past quarter, it was a preferred prescription for short-term treatment of dry eye disease. Furthermore, Kala explained that its expanding market access with Commercial and Medicare Part D health plans...Mark Iwicki, Chairman, President, and Chief Executive Officer of Kala Pharmaceuticals, explained, “We are encouraged by the very positive feedback we consistently receive from physicians and patients, who describe EYSUVIS as an effective and comfortable medicine and look forward to building on this foundation as we continue with the EYSUVIS launch. In parallel, we continue to promote INVELTYS and are advancing our pipeline of new chemical entities for front and back of the eye diseases, as we work to build a robust and sustainable portfolio of innovative treatments.” " Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
NASDAQ:KALA
by PennyStocks101